Cargando…
Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry
BACKGROUND: Despite the increasing number of cases of secondary antibody deficiency (SAD) and immunoglobulin (Ig) utilization, there is a paucity of data in the literature on clinical and patient-reported outcomes in this population. OBJECTIVE: To describe immunoglobulin utilization patterns, clinic...
Autores principales: | Abadeh, Armin, Shehadeh, Sarah, Betschel, Stephen, Waserman, Susan, Cameron, Donald William, Cowan, Juthaporn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653498/ https://www.ncbi.nlm.nih.gov/pubmed/37971974 http://dx.doi.org/10.1371/journal.pone.0294408 |
Ejemplares similares
-
Differential immunomodulation of T-cells by immunoglobulin replacement therapy in primary and secondary antibody deficiency
por: Dinh, Tri, et al.
Publicado: (2019) -
Polyvalent Immunoglobulin as a Potential Treatment Option for Patients with Recurrent COPD Exacerbations
por: Unninayar, Dana, et al.
Publicado: (2021) -
Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada
por: Gerth, William C, et al.
Publicado: (2014) -
Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada
por: Gerth, William C, et al.
Publicado: (2014) -
Cutaquig(®) Is Well Tolerated in Immunodeficient Patients Who Did Not Tolerate Other Subcutaneous Immunoglobulin Products
por: Brownlee, Sydney, et al.
Publicado: (2022)